Navigation Links
BD Biosciences to Distribute FCS Express
Date:1/26/2009

> Contact Information: David Novo Jim Harper President Software Product Manager De Novo Software BD Biosciences info@denovosoftware.com jim_harper@bd.com 213.814.1240 408.954.2561

About De Novo Software

De Novo Software provides integrated solutions for the life sciences, primarily in the field of flow cytometry data analysis. Its primary product, FCS Express, is used by over one thousand laboratories worldwide for research purposes, and dozens of clinical laboratories for high throughput clinical analysis. As the only third-party flow analysis software registered with the FDA for in-vitro diagnostic use, FCS Express is the analysis tool of choice for the clinical laboratory. In addition, De Novo Software has extensive experience creating custom data analysis solutions and integrating with large scale LIS and HIS systems. For more information, please visit www.denovosoftware.com.


'/>"/>
SOURCE De Novo Software
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
2. Cell Biosciences Introduces Kits for Oncoprotein Analysis
3. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
4. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
5. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
6. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
7. Cell Biosciences Delivers Next Generation System to Stanford University
8. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
9. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
10. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
11. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 21, 2014 The ... the inorganic refrigerants market in Americas with analysis ... TOC of the Americas Inorganic Refrigerants Market report, ... provided. This also provides a glimpse of the ... is supported by various tables and figures. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Involution ... the release of a new infographic, Understanding Ebola ... create a beautifully designed, easy to follow informative tool ... areas of outbreak, symptoms and prevention. , "As the ... that the 2014 Ebola outbreak represents not only a ...
(Date:10/22/2014)... Ras Al Khaimah, UAE (PRWEB) October 22, 2014 ... in game-changing life science and healthcare projects, announces the ... MBBS MRCGP DRCOG DCH to its advisory team. Dr. ... research advisory team. , A graduate of ... Dr. Siddiqui was subsequently degreed in medicine in 2001. ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 2The Americas Inorganic Refrigerants Market is estimated to grow to $71.6 million by 2018 - New Report by MicroMarket Monitor 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... support Phase 3 Trials for Crohn,s Disease, Pouchitis and ... ... Ocera Therapeutics, a,biopharmaceutical company focused on the licensing, development ... and liver diseases, has announced the completion of a,$35.5 million ...
... Million; GAAP EPS $0.34; ... Adjusted EPS $0.35, Fiscal Year 2007: Total Net Revenue Reaches $2.50 ... $1.27; 2007 Adjusted EPS ... leading specialty pharmaceutical,company, today reported fourth quarter and full year 2007 financial results,for its ...
... COLUMBIA, Md., Feb. 20 Cylex, Inc., today ... research study in,which the level of cellular immune ... proprietary ImmuKnow(R) immune cell,function test was found to ... early,acute transplant rejection and unstable kidney function in ...
Cached Biology Technology:Ocera Therapeutics Closes $35.5 Million Series C Financing 2Ocera Therapeutics Closes $35.5 Million Series C Financing 3Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 2Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 3Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 4Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 5Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 6Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 7Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 8Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 9Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 10Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 11Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 12Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 13Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 14Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 15Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 16Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 17Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook 18New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection 2New Independent Research Study Indicates That Cylex's ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection 3
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... of the planet,s leading questions is how to produce ... variable climate. The Food and Agriculture Organization of the ... over the next 40 years to feed a growing ... the necessary rise in food production. Plants—grains, cereals, ... supporting livestock. Current research must tap into our ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... are lost within two decades, according to a new study ... culprits? Old e-mail addresses and obsolete storage devices. "Publicly ... says Tim Vines, a visiting scholar at the University of ... time and place, and is thus irreplaceable, and many other ...
... 19, 2013 A high-fat diet affects the molecular ... functions in the liver, UC Irvine scientists have found. ... distress ailments, such as diabetes, obesity and high blood ... also discovered that returning to a balanced, low-fat diet ...
... This news release is available in ... team of researchers from Bielefeld University, Germany, the Centre for Genomic ... Genetics (MPIMG), Department of Vertebrate Genomics (H. Lehrach) in Berlin and ... to sequence and analyse for the first time the sweet genes ...
Cached Biology News:Nutrition influences metabolism through circadian rhythms, UCI study finds 2Deciphering the secret of the sugar beet 2
... This BioSafe room is configured ... testing and chemical analysis. Panels are ... are easy to wipe down and ... Unique double-wall panel design creates strong, ...
... Phosphate Sensor is a highly sensitive ... This product is a purified form of ... the fluorophore MDCC, which is sensitive to ... inorganic phosphate by Phosphate Sensor is rapid ...
... This benchtop ductless exhaust hood ... allowing safe indoor release of exhaust. ... contaminants. Over 28" of vertical clearance ... glassware. Includes polypropylene spill tray; options ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Biology Products: